Dyne Therapeutics (DYN) Total Liabilities (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Total Liabilities of $291.9 million for Q2 2026, up 85.25% year-over-year from $157.5 million in Q2 2025, and up 35.82% quarter-over-quarter from $214.9 million in Q1 2026.
Dyne Therapeutics (DYN) Total Liabilities (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Total Liabilities for 8 consecutive years, with $291.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 85.25% year-over-year to $291.9 million; the TTM figure through Jun 2026 stood at $291.9 million (up 85.25% YoY), while the FY2025 annual figure was $214.8 million, up 249.91% from the prior year.
- Total Liabilities rose to $291.9 million in Q2 2026 per DYN's latest filing, from $214.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $291.9 million in Q2 2026 and bottomed at $44.2 million in Q1 2024.
- Historically, Total Liabilities has averaged $97.4 million across 5 years, with a median of $53.6 million in 2022.
- Annual changes were most pronounced in 2024 — Total Liabilities dropped 16.8% — and 2026, when it soared 312.46%.
- Dyne Therapeutics' Total Liabilities stood at $54.0 million in 2022, then soared by 36.75% to $73.8 million in 2023, then decreased by 16.8% to $61.4 million in 2024, then jumped by 249.91% to $214.8 million in 2025, then jumped by 35.86% to $291.9 million in 2026.
- Business Quant data shows DYN's Total Liabilities at $291.9 million in Q2 2026, $214.9 million in Q1 2026, and $214.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 291.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 291.86 Mn |
| Mar 31, 2026 | 214.90 Mn |
| Dec 31, 2025 | 214.83 Mn |
| Sep 30, 2025 | 175.28 Mn |
| Jun 30, 2025 | 157.55 Mn |
| Mar 31, 2025 | 52.10 Mn |
| Dec 31, 2024 | 61.40 Mn |
| Sep 30, 2024 | 63.30 Mn |
| Jun 30, 2024 | 50.69 Mn |
| Mar 31, 2024 | 44.22 Mn |
| Dec 31, 2023 | 73.79 Mn |
| Sep 30, 2023 | 53.21 Mn |
| Jun 30, 2023 | 44.54 Mn |
| Mar 31, 2023 | 46.71 Mn |
| Dec 31, 2022 | 53.96 Mn |
| Sep 30, 2022 | 49.94 Mn |
| Jun 30, 2022 | 52.97 Mn |
| Mar 31, 2022 | 51.30 Mn |
| Dec 31, 2021 | 57.47 Mn |
| Sep 30, 2021 | 52.76 Mn |